Ken Phelps, President and CEO

Ken Phelps used more than three decades of experience in the health science and services industry to found Camargo Pharmaceutical Services in 2003.   As an expert in drug development, specifically the 505(b)(2) regulatory approval pathway, Phelps has aided in the successful FDA approval of numerous compounds.

Prior to founding Camargo, his broad background in drug development had led to a number of executive level-assignments in the areas of quality control, project management and regulatory, clinical and medical affairs at Duramed Pharmaceuticals (now Barr Pharmaceuticals).

Prior to his work for Duramed, Mr. Phelps held a number of positions at Merrell National Labs, which merged to become Merrell Dow and eventually evolved into Aventis. At Merrell he had global responsibility for quality assurance, quality control and processing technology with an assignment based in Milan, Italy and later directed IT for multi-national manufacturing operations, leading to technical improvements in R&D, accounting and manufacturing operations.

He began his career synthesizing, characterizing and performing drug metabolism studies of potential carcinogens with the Eppley Center for Research in Cancer. He also gained early entrepreneurial experience by establishing a laboratory and manufacturing sterile blood collection tubes.

Mr. Phelps has a BS in Chemistry from the University of Nebraska.